Skip to main content
SpringerLink
Log in

Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

This study aimed to compare the changes and determine the clinical significance of carbohydrate antigens CA242, CA199, CA125, carcinoembryonic antigen (CEA), and tumor-specific growth factor (TSGF) before and after cryoablation by Cryocare system. Thirty-one pancreatic cancer patients were selected to receive cryoablation by Cryocare system. The serum expression levels of CA242, CA199, CA125, CEA, and TSGF before and 1 month after treatment were determined. Meanwhile, the serum level of these factors was also determined in 31 healthy volunteers. The parameter changes were analyzed with the clinical pathological data. The serum levels of CA242, CA199, CA125, CEA, and TSGF in the pancreatic cancer group were significantly higher than those of the control group both before and after the cryoablation treatment (P < 0.05). The serum CA199, CEA, and TSGF dramatically decreased 1 month after the treatment, which were statistically different (P < 0.05). The positive rates of serum CA242, CA199, CA125, and CEA in the pancreatic cancer group were much higher than those in the control group both before and after treatment (P < 0.05), and the positive rate of TSGF was significantly higher than that of the control group before the treatment (P < 0.05). The positive rate of CA199, CEA, and TSGF after the treatment was significantly lower than that before the treatment (P < 0.05). Serum level of CA242 was correlated with the tumor diameter, clinical staging, tumor differentiation, lymph node, and liver metastasis (P < 0.05). Except gender, CA199 was correlated with all the other clinical pathological parameters (P < 0.05). The serum levels of CA125 and CEA were correlated with all the other clinical pathological parameters (P < 0.05). The serum level of TSGF was only correlated with tumor differentiation (P < 0.05). Cryoablation treatment by Cryocare system can decrease the serum levels of CA199, CEA, TSGF, and the positive rate. Serum CA199, CEA, and TSGF can be important index for pancreatic cancer treatment assessment. Serum levels of CA242, CA199, CA125, and CEA are of great clinical value for metastasis assessment and prognosis in pancreatic cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jelski, W., Kutylowska, E., Laniewska-Dunaj, M., et al. (2011). Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as candidates for tumor markers in patients with pancreatic cancer. Journal of Gastrointestinal and Liver Diseases, 20(3), 255–259.

    PubMed  Google Scholar 

  2. Gui, J. C., Yan, W. L., & Liu, X. D. (2014). CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: A meta-analysis. Clinical and Experimental Medicine, 14(2), 225–233.

    Article  CAS  PubMed  Google Scholar 

  3. Liu, H. M., Zhao, S. L., Qu, L. X., et al. (2011). Value of contrast-enhanced ultrasound imaging in monitoring malignant tumor during argon–helium cryosurgery. Nan Fang Yi Ke Da Xue Xue Bao, 31(9), 1622–1625.

    PubMed  Google Scholar 

  4. Zhou, G., Niu, L., Chiu, D., et al. (2012). Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-alpha and TSGF after cryosurgery in pancreatic cancer patients. Biotechnology Letters, 34(7), 1235–1241.

    Article  CAS  PubMed  Google Scholar 

  5. Wang, Z., & Tian, Y. P. (2014). Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Molecular and Clinical Oncology, 2(2), 265–268.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Huang, Z., & Liu, F. (2014). Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: A meta-analysis. Tumour Biology, 35(8), 7459–7465.

    CAS  PubMed  Google Scholar 

  7. Bao, B., Ali, S., Ahmad, A., et al. (2014). Differentially expressed miRNAs in cancer-stem-like cells: Markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells and Development, 23(16), 1947–1958.

    Article  CAS  PubMed  Google Scholar 

  8. Yoo, T., Lee, W. J., Woo, S. M., et al. (2011). Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 81(4), e623–e630.

    CAS  Google Scholar 

  9. Vainshtein, J. M., Schipper, M., Zalupski, M. M., et al. (2013). Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: Analysis of a prospective phase 1/2 dose escalation study. International Journal of Radiation Oncology Biology Physics, 86(1), 96–101.

    CAS  Google Scholar 

  10. Zhao, J. G., Hu, Y., Liao, Q., et al. (2014). Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer. World Journal of Gastroenterology, 20(19), 5875–5880.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Satoi, S., Yanagimoto, H., Toyokawa, H., et al. (2011). Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas, 40(3), 426–432.

    Article  CAS  PubMed  Google Scholar 

  12. Kanda, M., Fujii, T., Takami, H., et al. (2014). The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surgery Today, 44(9), 1692–1701.

    Article  CAS  PubMed  Google Scholar 

  13. Tzeng, C. W., Balachandran, A., Ahmad, M., et al. (2014). Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford), 16(5), 430–438.

    PubMed Central  Google Scholar 

  14. Li, X., Guo, X., Li, H., et al. (2014). Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer. Tumour Biology, 35(6), 5281–5286.

    CAS  PubMed  Google Scholar 

  15. Singh, S., Tang, S. J., Sreenarasimhaiah, J., et al. (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Digestive Diseases and Sciences, 56(8), 2491–2496.

    Article  CAS  PubMed  Google Scholar 

  16. Singh, S., Tang, S. J., Sreenarasimhaiah, J., et al. (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Digestive Diseases and Sciences, 56(8), 2491–2496.

    Article  CAS  PubMed  Google Scholar 

  17. Liu, H. M., Zhao, S. L., Qu, L. X., et al. (2011). Value of contrast-enhanced ultrasound imaging in monitoring malignant tumor during argon–helium cryosurgery. Nan Fang Yi Ke Da Xue Xue Bao, 31(9), 1622–1625.

    PubMed  Google Scholar 

  18. Bauer, T. M., El-Rayes, B. F., Li, X., et al. (2013). Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials. Cancer, 119(2), 285–292.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Pelzer, U., Hilbig, A., Sinn, M., et al. (2013). Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Frontiers in Oncology, 3, 155.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Kaur, S., Baine, M. J., Guha, S., et al. (2013). Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: Pathobiologic implications in diagnosing benign and malignant disease of the pancreas. Pancreas, 42(3), 494–501.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology Surgery, The First Affiliated Hospital of Henan University of Science and Technology, 24 Jinghua Road, Jianxi District, Luoyang, Henan Province, China

    Ye Chen, She-Gan Gao, Jian-Min Chen, Gong-Ping Wang, Zeng-Fang Wang, Bo Zhou, Can-Hui Jin, Yan-Tong Yang & Xiao-Shan Feng

Authors
  1. Ye Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. She-Gan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian-Min Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gong-Ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeng-Fang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bo Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Can-Hui Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan-Tong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao-Shan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Shan Feng.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Gao, SG., Chen, JM. et al. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients. Cell Biochem Biophys 71, 1287–1291 (2015). https://doi.org/10.1007/s12013-014-0345-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0345-2

Keywords

Search

Navigation